top of page

Virtuvax.nl Online

Ernst Soethout
23 aug 2016
1 minuten om te lezen

Follow Virtuvax on LinkedIn, Twitter or via www.virtuvax.nl .

Comments

Featured Posts

Virtuvax for collaboration on your innovation in vaccine development or your biosimilar

Virtuvax for collaboration on your innovation in vaccine development or your biosimilar

Virtuvax for collaboration on your innovation in vaccine development or your biosimilar

Virtuvax' innovation in vaccine industry “vaccine development skating on start-ups”

Virtuvax' innovation in vaccine industry “vaccine development skating on start-ups”

Virtuvax' innovation in vaccine industry “vaccine development skating on start-ups”

Recent Posts

Mucosis Announces Re-issue of Major Patent by US Patent Office USPTO

SynGEM publication paper of the month on ReSViNET

First-in-Human Results of SynGEM Demonstrate that the RSV Vaccine Is Well-Tolerated and Capable of I

New comment by UMC Utrecht on the SynGEM vaccine trial is a plea to consider the vaccine in an RSV c

Phase I clinical trial data of Mucosis intranasal vaccine against respiratory syncytial virus (RSV)

Virtuvax to attend DCVMN in Kunming

Virtuvax for collaboration on your innovation in vaccine development or your biosimilar

Matchmaking and contributing to a vaccine based Global insurance against Emerging Infections?

Virtuvax' innovation in vaccine industry “vaccine development skating on start-ups”

Meet Virtuvax @ BioWin Day 2016

Archive

Search By Tags

Follow Us

bottom of page